Southeast Asia Olmesartan Market was valued at US$ 322.8 million in 2022 and is projected to surpass a valuation of US$ 491.79 million by 2031 at a CAGRof 4.3% during the forecast period 2023–2031.
The Southeast Asia Olmesartan market has witnessed steady growth in recent years, driven by the rising prevalence of hypertension and cardiovascular diseases in the region. For instance, the prevalence of hypertension in Southeast Asia is high, with an estimated 25% of adults affected. The prevalence is highest in the Philippines, where 30% of adults are affected, and lowest in Thailand, where 17% of adults are affected. On the other hand, cardiovascular diseases are the leading cause of death in Southeast Asia, accounting for an estimated 30% of all deaths. The most common cardiovascular diseases in Southeast Asia are stroke, coronary heart disease, and heart failure.
The rising prevalence of hypertension in Southeast Asia has led to a considerable surge in the demand for Olmesartan, an effective blood pressure control medication. Additionally, the region's growing aging population, which is more susceptible to cardiovascular diseases, is expected to drive the demand for Olmesartan in the coming years. There is also an increasing awareness of the importance of cardiovascular health, resulting in the adoption of preventive measures, including the use of Olmesartan.
The continuous improvement of healthcare infrastructure, along with advancements in healthcare technologies like telemedicine and digital health solutions, has further contributed to the growth of the Olmesartan market in Southeast Asia.
To Get more Insights, Request A Free Sample
The escalating prevalence of hypertension in Southeast Asia serves as a major driver fueling the demand for Olmesartan in the region. Hypertension is a significant public health concern, with a substantial portion of the population affected by this condition. According to data from the World Health Organization (WHO), Southeast Asia has one of the highest rates of hypertension globally, affecting more than 25% of adults.
This increasing prevalence of hypertension is attributed to various factors, including sedentary lifestyles, poor dietary habits, and a rapidly aging population. As a result, the demand for effective antihypertensive medications, such as Olmesartan, has witnessed a considerable surge. Olmesartan, an angiotensin receptor blocker (ARB), is widely recognized for its efficacy in lowering blood pressure levels, making it a preferred choice among healthcare professionals.
Given the significant burden of hypertension in Southeast Asia and the need for efficient treatment options, the rising prevalence of hypertension serves as a robust driver propelling the growth of the Olmesartan market. As healthcare awareness and access to quality medical care continue to improve in the region, the demand for Olmesartan is expected to grow further in the coming years.
A notable trend in the Southeast Asia Olmesartan market is the increasing adoption of preventive measures for cardiovascular health. There is a growing awareness among the population about the importance of maintaining cardiovascular health and taking proactive steps to prevent complications associated with hypertension. This shift in mindset has led to a significant increase in the adoption of preventive cardiovascular health measures, including the use of antihypertensive drugs like Olmesartan.
Governments, healthcare organizations, and medical professionals are actively promoting preventive strategies to combat the rising burden of cardiovascular diseases in the region. This includes initiatives aimed at raising awareness about hypertension, promoting regular health check-ups, encouraging lifestyle modifications, and emphasizing the importance of early intervention.
As a result of these efforts, the demand for Olmesartan has witnessed substantial growth. Olmesartan, known for its effectiveness in controlling blood pressure and reducing the risk of cardiovascular events, is increasingly being prescribed to individuals at risk of or diagnosed with hypertension. This trend is supported by statistics revealing the alarming impact of cardiovascular diseases in Southeast Asia. The Global Burden of Disease Study reported that cardiovascular diseases accounted for approximately 40% of all deaths in the region.
As the emphasis on preventive cardiovascular health measures continues to grow, the adoption of Olmesartan is expected to further increase in Southeast Asia. Market players in the region have an opportunity to cater to this trend by offering educational initiatives, awareness campaigns, and innovative solutions that promote the use of Olmesartan as a key component of preventive cardiovascular care.
A significant restraint in the Southeast Asia Olmesartan market is the availability of alternative antihypertensive therapies. The market faces competition from other medications, both generic and branded, that offer similar efficacy in controlling blood pressure levels. For instance, angiotensin receptor blockers (ARBs), to which Olmesartan belongs, are available in various options, providing patients and healthcare professionals with alternatives to choose from. Additionally, generic versions of Olmesartan are also available, offering cost-effective options.
According to a report, the availability of generic versions of Olmesartan is expected to hinder the market growth. Market players need to address this restraint by highlighting the unique benefits and features of Olmesartan, such as its long-lasting effect and superior cardiovascular outcomes, to differentiate it from alternatives and maintain its market position.
In terms of dose, the 20 mg segment emerged as the leading revenue generator, reaching $123.10 million in 2022 in the Southeast Asia Olmesartan market. This segment is expected to maintain its dominance throughout the forecast period, displaying a robust compound annual growth rate (CAGR) of 4.9%.
The popularity of the 20 mg dose can be attributed to its effectiveness in controlling blood pressure levels while minimizing the risk of adverse effects. Additionally, it offers a balanced approach for patients requiring moderate to high dosage strength. The segment's continued dominance can be attributed to its wide acceptance among healthcare professionals and its proven efficacy in managing hypertension.
Among the various applications, the high blood pressure segment accounted for the highest revenue of $175.59 million in 2022 in the Southeast Asia Olmesartan market. It is expected to maintain its dominance throughout the forecast period, exhibiting a healthy CAGR of 4.7%.
The high prevalence of hypertension in the region and the increasing awareness about its complications have contributed to the significant demand for Olmesartan in treating high blood pressure. Moreover, the effectiveness of Olmesartan in reducing the risk of cardiovascular events has further propelled its adoption in managing this condition.
The adult segment led the Southeast Asia Olmesartan market, generating the highest revenue of $267.89 million in 2022. This segment is expected to continue its dominance over the forecast period, displaying a healthy CAGR of 4.2%. The high prevalence of hypertension among the adult population, coupled with the growing aging population in the region, has driven the demand for Olmesartan in the adult segment.
Moreover, the emphasis on managing hypertension and preventing cardiovascular diseases in adults has further contributed to the segment's growth. The availability of various dosage forms suitable for adults and the wide acceptance of Olmesartan as a first-line treatment for hypertension in adults have also boosted its market share.
To Understand More About this Research: Request A Free Sample
Indonesia, as the largest country in Southeast Asia, plays a pivotal role in the Olmesartan market within the region. With a population of over 270 million, the country contributes significantly to the revenue of the regional market. In 2022 alone, Indonesia generated more than $89 million in revenue, cementing its dominance in the Southeast Asia Olmesartan market.
Indonesia's leading position can be attributed to multiple factors, including the high prevalence of hypertension, diabetes, and cardiovascular diseases within the country. Hypertension affects a considerable portion of the Indonesian population, with statistics showing that over 30% of adults suffer from this condition. Additionally, diabetes has emerged as a growing health concern, impacting around 10% of the population. The coexistence of hypertension and diabetes in many individuals further increases the demand for Olmesartan, which effectively controls blood pressure levels.
Furthermore, cardiovascular diseases pose a significant health burden in Indonesia, accounting for a significant number of deaths. The need for effective antihypertensive medications, such as Olmesartan, has risen in response to these alarming statistics, driving the market growth in the country.
With the continuous development of Indonesia's healthcare infrastructure and increasing awareness of cardiovascular health, the demand for Olmesartan is expected to grow even further. Market players can capitalize on this opportunity by focusing on expanding their presence, establishing strategic partnerships, and tailoring their marketing efforts to cater to the specific needs of the Indonesian market.
By Dose
By Application
By End Users
By Distribution Channel
By Country
LOOKING FOR COMPREHENSIVE MARKET KNOWLEDGE? ENGAGE OUR EXPERT SPECIALISTS.
SPEAK TO AN ANALYST
.png)
Features | Type of License | |||
 Single User |   Multi User |  Corporate | ||
| e-Access | ✓ | ✓ | ✓ | |
User Sharing | 1 User Only | 2-6 Users | Unlimited within Company/Enterprise | |
⨉ | ⨉ | ✓ | ||
Free Customization | Up To 30 hrs work | Up To 60 hrs work | Up To 80 hrs work | |
Deliverable |
| ✓ | ✓ | ✓ |
| ⨉ | ✓ | ✓ | |
| ⨉ | ⨉ | ✓ | |
Analyst Support | 4 Month Post purchase | 7 Month Post purchase | One Year Post purchase | |
Free Report update in next update cycle | ⨉ | ⨉ | ✓ | |
Free Industry Update (Within 180 days) | ⨉ | ⨉ | ✓ | |
Benefit | Up to 20% off on next purchase | Up to 30% off on next purchase | Up to 40% off on next purchase | |
| Report ID: AA0723513 | Delivery: 2 to 4 Hours 
.svg)
